Valproic Acid / Depakote

Valproic acid (Depakote, Depakene) is a broad-spectrum antiepileptic that works by increasing gamma-aminobutyric acid (GABA) levels in the brain and blocking voltage-gated sodium and calcium channels. This multi-mechanism action makes it effective for absence, tonic-clonic, partial, and myoclonic seizures — a wider range than phenytoin or most newer agents. It is also used for bipolar mania and migraine prophylaxis. The therapeutic serum level is 50–100 mcg/mL. Hepatotoxicity is the most dangerous adverse effect, particularly in children under 2 on polytherapy; monitor liver function tests (AST, ALT) at baseline and periodically. Valproic acid carries a boxed warning for teratogenicity and is contraindicated in pregnancy for migraine prophylaxis; it is associated with neural tube defects (spina bifida), so women of childbearing age require pregnancy counseling and reliable contraception before starting therapy. (Legacy FDA Category X may still appear on NCLEX.) It causes dose-dependent thrombocytopenia AND independently inhibits platelet aggregation — both contribute to bleeding risk; monitor CBC with platelets. Monitor ammonia levels if the client develops unexplained confusion or lethargy — valproic acid can cause hyperammonemia even with normal LFTs. Other common side effects include GI upset (give with food or use enteric-coated formulation), weight gain, tremor, and alopecia. Pancreatitis, though rare, requires immediate evaluation if the client reports severe abdominal pain with nausea and vomiting. Key drug interaction: valproic acid inhibits lamotrigine metabolism, significantly raising lamotrigine levels and the risk of Stevens-Johnson syndrome; dose adjustments are required when used together.